İpek YÖNAL HİNDİLERDEN, Fehmi HİNDİLERDEN, Aynur ADAY, Meliha NALÇACI, Ezgi ŞAHİN

The impact of JAK2V617F mutation on Philadelphia-negative myeloproliferative neoplasms

Background/aim: JAK2V617F mutation is expressed in almost all polycthemia vera (PV), 55% of essential thrombocythemia (ET), and 65% of primary myelofibrosis (PMF) patients. Studies investigating phenotypic effects of JAK2V617F mutation on Philadelphianegative myeloproliferative neoplasms (Ph-negative MPNs) have reported controversial results. This study aims to determine the impact of JAK2V617F mutation on clinical phenotype and outcome in Ph-negative MPNs. Materials and methods: Clinical correlates and long-term prognostic relevance of the JAK2V617F mutation were analyzed in 410 Phnegative MPNs-170 ET, 135 PV, 105 PMF- from two institutions and followed for a mean of 76.7 months (SD 62.1) (mean 87 months (SD 67.8), 70.4 months (SD 56.4), 68 months (SD 57.4), respectively for ET, PV, and PMF). Two hundred and twenty-eight patients were genotyped for JAK2V617F mutation using the JAK2 Ipsogen MutaScreen assay, which involves allele-specific polymerase chain reaction (PCR), and 182 patients were genotyped using melting curve analysis. Results: In PV patients, JAK2V617F mutation was associated with higher rate in females, lower hemoglobin (Hgb) level, higher leukocyte and platelet count and higher prevalence of thrombosis (p = 0.008, p = 0.018, p = 0.001, p = 0.001, and p = 0.035, respectively). In ET patients, JAK2V617F mutation was associated with higher Hgb and hematocrit (Hct) levels and lower platelet count (p = 0.001, p = 0.001, and p = 0.001, respectively). JAK2V617F-negative ET patients showed a trend towards higher rate of leukemic transformation (p = 0.061). JAK2V617F mutation-positive PMF patients had higher leukocyte count, greater spleen size and showed a trend towards higher Hgb level (p = 0.019, p = 0.042, and p = 0.056, respectively). Among PMF patients with JAK2V617F mutation, the rate of female patients was lower (p = 0.001). Overall survival (OS) in Dynamic International Prognostic Scoring System (DIPSS) - plus high risk PMF patients was shorter compared to the other risk groups (p = 0.001). Leukemia-free survival (LFS) was shorter in DIPSS - plus high risk PMF patients than the other risk groups (p = 0.005). In the entire cohort of Ph-negative MPN patients, JAK2V617F mutation was associated with higher leukocyte count, higher Hgb and Hct levels and lower platelet count, higher frequency of phlebotomies, a trend towards older age, a trend towards greater spleen size, a trend towards a higher prevalence of risk factors for cardiovascular diseases and thrombosis (p = 0.001, p = 0.005, p = 0.001, p = 0.003, p = 0.004, p =0.052, p = 0.056, p = 0.052, and p = 0.059, respectively). Conclusion: In our study population, it was demonstrated that the presence of JAK2V617F mutation in ET patients was associated with PV-like phenotype. Our study also showed that the presence of the JAK2V617F mutation was associated with increased risk of thrombotic complications. Our results suggest that JAK2V617F mutation is associated with a more pronounced myeloproliferative phenotype in PMF patients. In a large number of Ph-negative MPN patients, our findings support that JAK2V617F mutation is associated with a more aggressive phenotype.

PDF

___

1. Hoffman R, Prchal JT, Samuelson S, Ciurea SO, Rondelli D. Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment. Biology of Blood and Marrow Transplantation 2007 Jan; 13 (1 Suppl 1): 64-72. doi: 10.1016/j.bbmt.2006.11.003
2. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. American Journal of Hematology 2020 Dec; 95 (12): 1599-1613. doi: 10.1002/ajh.26008
3. Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. American Journal of Hematology 2021 Jan; 96 (1): 145-162. doi: 10.1002/ajh.26050
4. Bertozzi I, Peroni E, Coltro G, Bogoni G, Cosi E et al. Thrombotic risk correlates with mutational status in true essential thrombocythemia. European Journal of Clinical Investigation 2016 Aug; 46 (8): 683-689. doi:10.1111/eci.12647
5. Qin Y, Wang X, Zhao C, Wang C, Yang Y. The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis. International Journal of Hematology 2015 Aug; 102 (2): 170- 180. doi: 10.1007/s12185-015-1808-y
6. Zhu JF, Liu Y, Liu P, Jia MF, Cheng J et al. JAK2V617F mutation in the patients with myeloproliferative disorder and its relation with clinical characteristics. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Aug; 19 (4): 916-920 (in Chinese).
7. Duletić AN, Dekanić A, Hadzisejdić I, Kusen I, Matusan-Ilijas K et al. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms. Collegium Antropologicum 2012 Sep; 36 (3):859-865.
8. Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA et al. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. British Journal of Haematology 2005; 131: 320–328. doi: 10.1111/j.1365-2141.2005.05776.x
9. Yönal İ, Dağlar-Aday A, Akadam-Teker B, Yılmaz C, Nalçacı M et al. Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis. Turkish Journal of Haematology 2016 Jun 5; 33 (2): 94-101. doi: 10.4274/tjh.2014.0136
10. Borowczyk M, Wojtaszewska M, Lewandowski K, Gil L, Lewandowska M et al. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. Thrombosis Research 2015 Feb; 135(2): 272-280. doi: 10.1016/j.thromres.2014.11.006
11.Chao HY, Fan Z, Zhang R, Shen YM, Chen W et al. Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms. Zhonghua Zhong Liu Za Zhi 2009 Jul; 31(7):510-514 (in Chinese).
12. Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. British Journal of Haematology.2005; 131:208-213. doi: 10.1111/j.1365-2141.2005.05764.x
13. Speletas M, Katodritou E, Daiou C, Mandala E, Papadakis E et al. Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders. Leukemia Research 2007 Aug; 31(8): 1053-1062. doi: 10.1016/j.leukres.2006.09.005
14. Soliman EA, El-Ghlban S, El-Aziz SA, Abdelaleem A, Shamaa S et al. JAK2, CALR, and MPL Mutations in Egyptian Patients With Classic Philadelphia-negative Myeloproliferative Neoplasms. Clinical Lymphoma Myeloma Leukemia 2020 Oct; 20 (10): e645-e651. doi: 10.1016/j.clml.2020.05.011
15. Campbell PJ, Griesshammer M, Dohner K, Dohner H, Kusec R et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006; 107: 2098–2100. doi: 10.1182/blood-2005-08-3395
16. Chim CS, Sim JP, Chan CC, Kho BC, Chan JC et al. Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: a multivariate analysis by Cox regression in 141 patients. Hematology 2010 Aug; 15(4): 187-192. doi: 10.1179/102453309X125833471139 33
17. Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007; 110: 4030–4036. doi: 10.1182/blood-2007-07-099184
18. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19; 127 (20): 2391-2405. doi: 10.1182/blood-2016-03-643544
19. Gangat N, Caramazza D, Vaidya R, George G, Begna K et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. Journal of Clinical Oncology 2011 Feb 1; 29 (4): 392-397. doi: 10.1200/JCO.2010.32.2446
20. Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. American Journal of Hematology 2013; 88: 141-150. doi: 10.1002/ajh.23384
21. Chae H, Lee JH, Lim J, Jung SW, Kim M et al. Usefulness of realtime semi-quantitative PCR, JAK2 MutaScreen kit for JAK2 V617F screening. The Korean Journal of Laboratory Medicine 2009; 29:243-248 (in Korean). doi:10.3343/kjlm.2009.29.3.243
22. Murugesan G, Aboudola S, Szpurka H, Verbic MA, Maciejewski JP et al. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. American Journal of Clinical Pathology 2006; 125: 625–633. doi: 10.1309/TK0X-L917-XK2V-LRPQ
23. Mejía-Ochoa M, Acevedo Toro PA, Cardona-Arias JA. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018. BMC Cancer 2019 Jun 17; 19 (1): 590. doi: 10.1186/s12885-019-5764-4
24. Hsiao HH, Yang MY, Liu YC, Lee CP, Yang WC et al. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia. Experimental Hematology 2007 Nov; 35 (11): 1704-1707. doi:010.1016/j.exphem.2007.08.011
25. Wong GC, Kam GL, Koay ES. JAK2 mutations in Asian patients with essential thrombocythaemia. Internal Medicine Journal.2011 Feb; 41(2):191-196. doi: 10.1111/j.1445-5994.2010.02199.x
26. Saki N, Shirzad R, Rahim F, Saki Malehi A. Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis.Clinical Translational Oncology 2017 Jul; 19 (7): 874-883. doi: 10.1007/ s12094-017-1618-1
27. Vu HA, Thao TT, Dong CV, Vuong NL, Chuong HQ et al. Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia. The Asian Pacific Journal of Cancer Prevention. 2019 Sep 1;20(9):2775-2780. doi: 10.31557/ APJCP.2019.20.9.2775
28. Pósfai É, Marton I, Király PA, Kotosz B, Kiss-László Z, Széll M et al. Pathology and Oncology Research 2015 Jul; 21 (3): 751-758. doi: 10.1007/s12253-014-9885-4.
29. Vytrva N, Stacher E, Regitnig P, Zinke-Cerwenka W, Hojas S et al. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F. The Archives of Pathology & Laboratory Medicine 2014 Sep;138 (9): 1203-1209. doi: 10.5858/arpa.2013-0018-OA
30. Palandri F, Ottaviani E, Salmi F, Catani L, Polverelli N et al. JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients. Leukemia Lymphoma 2009 Feb;50 (2) :247-253. doi: 10.1080/10428190802688152
31. Zhang S, Qiu H, Fischer BS, Li W, Duan L et al. J.JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera. Leukemia Lymphoma 2008 Apr; 49 (4): 696-699. doi: 10.1080/10428190701885537
32. Almedal H, Vorland M, Aarsand AK, Grønningsæter IS, Bruserud Ø et al. Myeloproliferative neoplasms and JAK2 mutations. Tidsskr Nor Laegeforen 2016 Dec 6; 136 (22): 1889-1894. doi: 10.4045/tidsskr.16.0128
33. Ojeda MJ, Bragós IM, Calvo KL, Williams GM, Carbonell MM et al. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms. Hematology 2018 May; 23 (4): 208-211. doi: 10.1080/10245332.2017.1385891
34. Lin X, Huang H, Chen P. Retrospective analysis of the clinical features of 172 patients with BCR-ABL1-negative chronic myeloproliferative neoplasms. Molecular Cytogenetics 2020 Feb 17; 13:18. doi: 10.1186/s13039-020-0471-z
35. Hu L, Pu L, Ding Y, Li M, Cabanero M et al. Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms. Hematology 2017 Jul; 22 (6): 354-360. doi: 10.1080/10245332.2016.1267830
36. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL,et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005 Dec 3; 366 (9501): 1945-1953. doi: 10.1016/S0140-6736(05)67785-9
37. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008; 22:1299-1307. doi: 10.1038/leu.2008.113
38. Yuan LY, Li H, Chen GA, Ji DX, Gao LL et al. Incidence of JAK2V617F mutation in myeloproliferative diseases and its clinical significance. Zhejiang Da Xue Xue Bao Yi Xue Ban 2010 Mar; 39 (2): 202-206 (in Chinese).
39. Ibrahim IK, Hassan R, Ali EW, Omer A. Polycythaemia Vera among Sudanese Patients with Special Emphasis on JAK2 Mutations. The Asian Pacific Journal of Cancer Prevention 2019 Jan 25; 20 (1): 41-44. doi: 10.31557/APJCP.2019.20.1.41
40. Panani AD. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications. Cancer Letters 2009 Oct; 18;284 (1):7-14. doi: 10.1016/j. canlet.2009.02.010
41. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA et al. A.Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008 Apr; 22 (4): 756-761. doi: 10.1038/sj.leu.2405097
42. Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009 Aug; 20;114 (8): 1477-1483. doi: 10.1182/ blood-2009-04-216044
43. Helbig G, Wieczorkiewicz A, Woźniczka K, Wiśniewska-Piąty K, Rusek A et al. The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis. Medical Oncology 2012 Dec; 29 (4): 2379-2384. doi: 10.1007/s12032-012-0190-3
44. Singh N, Sazawal S, Upadhyay A, Chhikara S, Mahapatra M et al. Correlation of JAK2V617F mutational status in primary myelofibrosis with clinico-hematologic characteristics and international prognostic scoring system scoring: a single center experience. Indian Journal of Pathology and Microbiology 2015 Apr-Jun; 58 (2): 187-191. doi: 10.4103/0377-4929.155311
45. Lieu CH, Wu HS, Hon YC, Tsai WH, Yang CF et al. Prevalence of the JAK2V617F mutation in Taiwanese patients with chronic myeloproliferative disorders. Internal Medicine Journal 2008 June; 38 (6): 422-426. doi: 10.1111/j.1445-5994.2007.01589.x
46. Karkucak M, Yakut T, Ozkocaman V, Ozkalemkas F, Ali R et al. Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera. Molecular Biology Reports 2012 September; 39 (9): 8663- 8667. doi: 10.1007/s11033-012-1721-x
47. Tefferi A, Lasho L, Schwager S, Strand S, Elliot M et al. The clinical phenotype of wild-type, heterozygous and homozygous JAK2V617F in polycythemia vera. Cancer 2006 Feb 1;106 (3): 631-635. doi: 10.1002/cncr.21645
48. Yonal-Hindilerden I, Daglar-Aday A, Akadam-Teker B, Yilmaz C, Nalcaci M et al. Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphianegative myeloproliferative neoplasms. Journal of Blood Medicine 2015 June 1; 6:157-175. doi: 10.2147/JBM.S78826